ClinicalTrials.gg
RecruitingNCT07856225Updated Oct 2, 2026

Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer

An observational study in Breast Neoplasms, Triple Negative Breast Neoplasms and HER2-Positive Breast Cancer, sponsored by Fundación Santa Fe de Bogota. Recruiting at 1 site in Colombia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's listed conditions name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fundación Santa Fe de Bogota · Observational

How we know · 9 judgments

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
370
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Triple Negative Breast Neoplasms with a site in Colombia — 6 open to participants now, 7 under way, 5 of them phase 3. Triple Negative Breast Neoplasms · Colombia.

Started
2025
with 4 others
Observational
Only one
of the 16
Registered
16th of 16
by date
Lead sponsor
1 of 16
Fundación Santa Fe de Bogota

Among the 16 studies in Triple Negative Breast Neoplasms with a site in Colombia, this one is one of 5 that started in 2025, is the only observational one, and was the 16th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

6 of the 16 studies in Triple Negative Breast Neoplasms with a site in Colombia are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Colombia have not opened yet or have stopped. Only those recruiting at a site in Colombia →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Triple Negative Breast Neoplasms with a site in Colombia, or all of them as a file.
02

Study summary

Breast cancer is the most common cancer in women worldwide. Its molecular classification, based on hormone receptors (estrogen and progesterone), HER2 and Ki-67, defines subtypes with different prognoses and treatments. In Colombia, there is limited information that integrates the clinical, treatment, sociodemographic and contextual characteristics of each subtype, and limited data on the direct medical costs of breast cancer care.

This retrospective cohort study will review the medical records of women 18 years or older with biopsy-confirmed breast cancer and a documented molecular subtype who were treated at Fundación Santa Fe de Bogotá (Bogotá, Colombia) between January 1, 2014 and December 31, 2024. It will describe each molecular subtype (luminal A, luminal B HER2-negative, luminal B HER2-positive, HER2-enriched, triple-negative and HER2-low) and evaluate the association of clinical, molecular and treatment characteristics with overall survival, progression-free survival, recurrence, treatment response and grade 3-4 adverse events. It will also explore the impact of the COVID-19 pandemic and health insurance regimen on outcomes, and estimate direct medical costs of breast cancer care by clinical stage and phase of care. The investigators will not assign or modify any treatment.

Read the detailed description

Background: Breast cancer is the most frequent malignancy in women, with an estimated 2.3 million new cases and 685,000 deaths worldwide in 2020. Molecular subtypes defined by hormone receptor, HER2 and Ki-67 status guide treatment and prognosis. Colombian studies have described the distribution of molecular subtypes, but no study has integrated clinical, molecular, treatment and contextual factors (such as the COVID-19 pandemic and health insurance regimen) in a single cohort, and cost data disaggregated by stage and phase of care are scarce.

Design: Single-center, observational, retrospective cohort study with an umbrella design that will support subtype-specific and treatment-specific secondary analyses, plus an economic component (cost-of-illness study with a micro-costing approach from the perspective of the Colombian health system).

Population: Women 18 years or older with histologically confirmed breast cancer and documented molecular subtype determined by immunohistochemistry and/or in situ hybridization, treated and/or followed at Fundación Santa Fe de Bogotá between January 1, 2014 and December 31, 2024. The sample size (370 patients) was calculated to estimate a 10% proportion of triple-negative breast cancer with 95% confidence and 3% precision.

Subtype-specific objectives: (1) triple-negative disease: pathological response, adverse events, recurrence, progression and survival, including the impact of the COVID-19 pandemic (diagnosis before versus after March 2020) and the influence of health insurance regimen; (2) luminal A disease: treatment patterns and outcomes, including high-risk patients who were candidates for abemaciclib or ribociclib; (3) luminal B HER2-positive disease: association of anti-HER2 therapy with pathological complete response, recurrence and survival; (4) luminal B HER2-negative disease: association of high Ki-67 with adjuvant or neoadjuvant chemotherapy decisions and outcomes; (5) HER2-enriched disease: anti-HER2 therapy, response, recurrence, survival and adverse events; (6) hormone receptor-positive/HER2-negative disease: outcomes with versus without CDK4/6 inhibitors; (7) HER2-low disease: recurrence and associated factors; and (8) direct medical costs by clinical stage and phase of care.

Data collection: Data will be abstracted from institutional records (clinical databases, pathology reports, electronic medical records and oncology follow-up records) into a REDCap database with access restricted to the research team. Variables include demographics, body mass index, menopausal status, histology, molecular subtype and biomarkers (hormone receptors, HER2, Ki-67), stage and metastatic sites, comorbidities (Charlson index), performance status, treatments (surgery, radiotherapy, endocrine therapy, chemotherapy, anti-HER2 therapy, CDK4/6 inhibitors and other systemic therapies), dates of diagnosis, progression, recurrence and death, and health insurance regimen. For the economic component, resource use will be identified for case types by clinical stage, therapeutic subtype and phase of care, coded with CUPS and CUM codes and valued with national cost and price sources.

Statistical analysis: Descriptive statistics will be used for the cohort. Bivariate associations will be assessed with chi-square or Fisher exact tests and t or Mann-Whitney tests. Overall survival, progression-free survival and time to recurrence will be analyzed with Kaplan-Meier curves and log-rank tests, followed by multivariable Cox regression adjusted for age, stage, comorbidities, treatment, insurance regimen and year of diagnosis, with verification of the proportional hazards assumption. Dichotomous outcomes (pathological complete response, grade 3-4 adverse events) will be analyzed with logistic regression. Interaction terms (for example, subtype by COVID-19 period) will be explored, the 10 events-per-variable rule will be applied, and collinearity will be assessed with the variance inflation factor. Missing data will be handled with multiple imputation when compatible with missing at random, or with sensitivity analyses otherwise. Costs will be presented by stage, therapeutic subtype and phase of care, with a 3% annual discount rate for horizons longer than one year and deterministic sensitivity analyses. Analyses will be performed in R.

Ethics: The study is classified as research without risk under Colombian Resolution 8430 of 1993 (retrospective documentary research), and additional informed consent is not required. The protocol (version 1.2) was approved by the Comité Corporativo de Ética en Investigación of Fundación Santa Fe de Bogotá (CCEI-18860-2025), and amendment version 2.0 (May 14, 2026) was approved in June 2026 (CCEI-20040-2026).

03

Conditions studied

  • Breast Neoplasms
  • Triple Negative Breast Neoplasms
  • HER2-Positive Breast Cancer
  • Hormone Receptor-Positive Breast Cancer

Browse trials for

Keywords

  • Molecular Subtype
  • Luminal A
  • Luminal B
  • HER2-Enriched
  • Triple-Negative
  • HER2-Low
  • Ki-67
  • CDK4/6 Inhibitors
  • Anti-HER2 Therapy
  • COVID-19
  • Health Insurance
  • Cost of Illness
  • Micro-Costing
  • Colombia
04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

This study's planned enrollment of 370 is above the median of 193 across 106 observational studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

Fundación Santa Fe de Bogota is the lead sponsor of 27 studies on the registry; 11 are open to participants now.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women 18 years or older with histologically confirmed breast cancer and a documented molecular subtype who were treated and/or followed at Hospital Universitario Fundación Santa Fe de Bogotá (Bogotá, Colombia) between January 1, 2014 and December 31, 2024, identified through institutional clinical databases, pathology reports and oncology follow-up records.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients older than 18 years with a histopathologically confirmed diagnosis of breast cancer.
  • Treated at Fundación Santa Fe de Bogotá between January 1, 2014 and December 31, 2024.
  • Available record of the tumor molecular subtype (luminal A, luminal B -negative, luminal B HER2-positive, HER2-enriched or triple-negative), determined by immunohistochemistry and/or in situ hybridization.

Exclusion criteria

Exclusion Criteria:

  • tumors from another primary site involving the breast (for example, breast metastases from another primary tumor).
  • Lesions of uncertain malignant potential or in situ tumors.
  • Incomplete or missing information on molecular subtype, treatment received or clinical outcomes.
  • Oncology follow-up outside the institution without adequate traceability of clinical outcomes.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

06

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
370 participants (estimated)
Patient registry
No

Groups and cohorts

  • Luminal A

    Drug: CDK4/6 Inhibitors · Other: Standard Breast Cancer Treatment

  • Luminal B HER2-Negative

    Drug: CDK4/6 Inhibitors · Other: Standard Breast Cancer Treatment

  • Luminal B HER2-Positive

    Drug: Anti-HER2 Therapy · Other: Standard Breast Cancer Treatment

  • HER2-Enriched

    Drug: Anti-HER2 Therapy · Other: Standard Breast Cancer Treatment

  • Triple-Negative

    Other: Standard Breast Cancer Treatment

Interventions

  • DrugCDK4/6 Inhibitors

    Drug page: PalbociclibStudies of PalbociclibPalbociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    CDK4/6 inhibitors (palbociclib, ribociclib or abemaciclib) combined with endocrine therapy, administered in routine clinical practice. The study does not assign or modify treatment; exposure data are abstracted retrospectively from medical records.

    Also known as: Palbociclib, Ribociclib, Abemaciclib

  • DrugTrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    HER2-targeted therapy (such as trastuzumab, pertuzumab or trastuzumab emtansine) administered in routine clinical practice. The study does not assign or modify treatment.

    Also known as: Trastuzumab, Pertuzumab, Trastuzumab Emtansine

  • OtherStandard Breast Cancer Treatment

    Surgery, radiotherapy, chemotherapy, endocrine therapy and other systemic therapies administered according to routine clinical practice. The study does not assign or modify treatment.

This study also gives PertuzumabStudies of PertuzumabPertuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., RibociclibStudies of RibociclibRibociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., AbemaciclibStudies of AbemaciclibAbemaciclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., Ado-Trastuzumab EmtansineStudies of Ado-Trastuzumab EmtansineAdo-Trastuzumab Emtansine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

07

What researchers measure

Primary outcomes

  1. Overall Survival

    Time frame: From diagnosis until death from any cause or last follow-up, assessed up to approximately 12 years

Secondary outcomes

  1. Progression-Free Survival

    Time frame: From diagnosis until progression, death or last follow-up, assessed up to approximately 12 years

  2. Tumor Recurrence

    Time frame: From completion of curative-intent treatment until recurrence or last follow-up, assessed up to approximately 12 years

  3. Treatment Response

    Time frame: At the end of each treatment line (neoadjuvant, adjuvant or systemic therapy), assessed up to approximately 12 years

  4. Incidence of Grade 3-4 Adverse Events

    Time frame: From treatment start until end of follow-up, assessed up to approximately 12 years

  5. Direct Medical Costs of Breast Cancer Care

    Time frame: Full care trajectory from diagnosis through follow-up, with a 3% annual discount rate for horizons longer than 1 year

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared. Data are obtained from a retrospective review of medical records without additional informed consent and are protected under Colombian personal data protection law (Law 1581 of 2012). Aggregated results will be published in peer-reviewed journals.

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Jun 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Dec 1, 2025
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07856225
Lead sponsor
Fundación Santa Fe de Bogota
Responsible party
Erick Andres Cantor Rizo (MD, Hematologist and Clinical Oncologist, Fundación Santa Fe de Bogota) — Principal investigator
First posted
Oct 2, 2026
Start date
Dec 1, 2025
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Erick Andrés Cantor Rizo, MD
Contact
erick.cantor@fsfb.org.co
+57 601 6030303
Erick Andrés Cantor Rizo, MD
principal investigator · Fundación Santa Fe de Bogotá

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion